Innoxel Lifesciences completes EU GMP inspection by Belgium's FAMHP
The audit was completed with zero critical and zero major observations
The audit was completed with zero critical and zero major observations
The 7,000th store was inaugurated in Ayodhya, Uttar Pradesh
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Subscribe To Our Newsletter & Stay Updated